Active Immunotherapy for Brain Cancer – Innovita Research

Nine children aged 2-7 years have been treated with anti-cancer immunotherapeutic vaccines. Before the onset of immunotherapy all patients exhibited signs of continued tumor growth. Over the follow-up period, patients received no systemic therapy other than immunotherapy. Two-year follow-up showed apparent long-term benefits from vaccine therapy in all patients. Final data analysis showed that all vaccine-treated patients were alive and led an active life. Although the results obtained in our clinical study are very promising, they must be interpreted with caution because of a small number of patients treated.

Related scientific publications:

  • Immunotherapy for Pediatric Brain Tumors.
    Sayour EJ, Mitchell DA. Brain Sci. 2017 Oct 21;7(10). pii: E137. doi: 10.3390/brainsci7100137. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/29065490
  • How immunotherapies are targeting the glioblastoma immune environment.
    Felthun J, Reddy R, McDonald KL. J Clin Neurosci. 017 Oct 14. pii: S0967-5868(17)31713-7. doi: 10.1016/j.jocn.2017.10.019. [Epub ahead of print] Review.
    https://www.ncbi.nlm.nih.gov/pubmed/29042147
  • Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.
    Ishikawa E, Yamamoto T, Matsumura A. Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):321-330. doi: 10.2176/nmc.nmc.ra.2016-0334. Epub 2017 May 24.
    https://www.ncbi.nlm.nih.gov/pubmed/28539528
  • Tumor Vaccines for Malignant Gliomas.
    Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Neurotherapeutics. 2017 Apr;14(2):345-357. doi: 10.1007/s13311-017-0522-2. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/28389997